Results 231 to 240 of about 325,525 (350)

Long-term immune protection after infant hepatitis B vaccination in children. [PDF]

open access: yesHum Vaccin Immunother
Tarigan Girsang R   +6 more
europepmc   +1 more source

Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study

open access: yesHepatology Research, EarlyView.
Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori   +17 more
wiley   +1 more source

Short‐Term Clinical Effects After Switching From Zinc Acetate Hydrate to Zinc Histidine Hydrate in Patients With Chronic Liver Disease

open access: yesHepatology Research, EarlyView.
Zinc deficiency is frequently seen in patients with chronic liver disease and is linked to poor appetite and nutritional status. We found that switching to zinc histidine hydrate increased zinc levels within a short period and was associated with improved appetite.
Yoshihito Uchida   +9 more
wiley   +1 more source

Prognostic Value of PALBI in Patients With Hepatocellular Carcinoma and Concurrent Chronic Kidney Disease: A Nomogram Development

open access: yesHepatology Research, EarlyView.
Patients with hepatocellular carcinoma (HCC) as well as chronic kidney disease (CKD) are high‐risk individuals, making it challenging to accurately predict their survival. We found that the PALBI grade model when combined with other patient's clinical and tumor‐related factors, forms a new and highly accurate prediction tool to estimate their ...
Jihye Lim   +2 more
wiley   +1 more source

Calibration and discrimination ability of the Dat'AIDS score in people living with HIV aged 70 years and older from the Dat'AIDS cohort

open access: yesHIV Medicine, EarlyView.
Abstract Objective The Dat'AIDS score was developed to predict 5‐year mortality risk in people living with HIV aged 60 and older. However, its validity in people living with HIV aged 70 years and older needed confirmation. Methods This was a multicentre prospective cohort study in the Dat'AIDS French cohort.
Abeo Mousse   +337 more
wiley   +1 more source

Home - About - Disclaimer - Privacy